Lightnews — Scholar-powered news

Jen L, PhD

@drjkyl.bsky.social

2.3K followers 13K following 240 posts

Executive Editor/Team Leader Open Access Science Journals Sage Publishing Opinions = mine http://linkedin.com/in/jlovick-editor #oncology #cancerresearch #medicine #biology #cardiology #neurology #microbiology #publichealth #healthcare #technology

Posts Media Videos Starter Packs

Pinned

Jen L, PhD @drjkyl.bsky.social · Feb 21

Introduction - PhD working in academic publishing, lead a team of amazing Managing Editors that support @sagepub.com @journals.sagepub.com 's Open Access Biomedical Journals. I'll be sharing recent articles from our journals that I find interesting. Happy to connect with researchers! 📖🔬🧪💊⚕️

Reposted by Jen L, PhD

Lingling Tian @linglingtian.bsky.social · 1d

🧬 Article collection on @tamedoncol.bsky.social: PARPi in Gynecologic Cancers. This collection highlights research on HRR genetic landscape, PARPi outcomes, oxaliplatin sequencing in BRCA-mutated ovarian cancer, and PARPi resistance with combination strategies. 📚 Explore more

Reposted by Jen L, PhD

Lingling Tian @linglingtian.bsky.social · 23h

Zolbetuximab is gaining attention as a targeted therapy for CLDN18.2-positive gastric and GEJ cancers.
This review dives into the science behind Claudin18.2 and the clinical promise of zolbetuximab, backed by SPOTLIGHT and GLOW trial data.
buff.ly/ok6eO7y
#Oncology #GastricCancer #Zolbetuximab

Reposted by Jen L, PhD

Cancer Control @cancer-control.bsky.social · 2d

BRCA1/2-mutant early #BreastCancer: review urges region-tailored testing in Latin America, MRI-first screening, and shared surgical decision making. Neo-adjuvant platinum can raise pCR, while adjuvant olaparib improves OS. #BRCA #TNBC #PARPi #Latam

Reposted by Jen L, PhD

Lingling Tian @linglingtian.bsky.social · 3d

Lung cancer is varying by region in risks and traits. A new article examines carcinogens, genetic predisposition, and molecular epidemiology. We seek submissions on geographic differences in lung cancer. Deadline: Dec 31, 2025 🔗 buff.ly/JCo9lJP #CancerResearch #LungCancer #GlobalHealth

Jen L, PhD @drjkyl.bsky.social · 5d

Real-world analysis of HER2-ultralow in HR+/HER2– metastatic breast cancer: prevalence and first-line chemotherapy outcomes
@tamedoncol.bsky.social
@linglingtian.bsky.social
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#cancertreatment #precisiononcology #ADCtherapy #oncology

Jen L, PhD @drjkyl.bsky.social · 5d

Design of an artificial natural killer cell mimicking system to target tumour cells
Journal of Tissue Engineering
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#immunotherapy #nanomedicine #NKcells #targeteddrugdelivery #openaccess

Jen L, PhD @drjkyl.bsky.social · 5d

Is Site of Radiation Therapy Associated With Pathologic Complete Response in Patients With Locally Advanced Esophageal Cancer?
@cancer-control.bsky.social
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#radiationoncology #radiotherapy #cancercare #cancertreatment #openaccess

Jen L, PhD @drjkyl.bsky.social · 5d

Identification of Potent HDAC6 Inhibitors for Breast Cancer Through Multi-Stage In Silico Modeling
Bioinformatics and Biology Insights
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#cancerresearch #precisiononcology #drugdiscovery #openaccess

Jen L, PhD @drjkyl.bsky.social · 5d

Cardioprotective effectiveness of SGLT2 inhibitors in older diabetic women with early-stage breast cancer following anthracycline- and/or trastuzumab-based treatment
@tamedoncol.bsky.social
@linglingtian.bsky.social
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#cardiooncology

Jen L, PhD @drjkyl.bsky.social · 5d

Understanding the Impact of Individual Nucleotide on Oxford Nanopore Current Signals With Interpretable Prediction Models
Bioinformatics and Biology Insights
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#nanoporesequencing #bioinformatics #DNAsequencing #MachineLearning #openaccess

Jen L, PhD @drjkyl.bsky.social · 5d

A patient-specific engineered tissue model of BAG3-mediated cardiomyopathy
Journal of Tissue Engineering
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#cardiactissueengineering #dilatedcardiomyopathy #iPSCmodels #precisioncardiology #openaccess

Jen L, PhD @drjkyl.bsky.social · 5d

Early and hereditary breast cancer: advances in risk stratification and imaging approaches
@tamedoncol.bsky.social
@linglingtian.bsky.social
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#precisiononcology #radiomics #hereditarycancer #IAIinHealthcare #openaccess

Jen L, PhD @drjkyl.bsky.social · 5d

The CHD Protein, Kismet, Restricts Synaptic BMP Signaling at Glutamatergic Synapses
Neuroscience Insights
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#chromatinremodeling #synapticplasticity #neurodevelpmentaldisorders #openaccess

Jen L, PhD @drjkyl.bsky.social · 5d

New article shows Claudin 18.2 expression does not impact immunotherapy outcomes in Advanced Gastric Cancer treatment
@tamedoncol.bsky.social
@linglingtian.bsky.social
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#cancertreatment #oncology #immunotherapy #chemotherapy #openaccess

Jen L, PhD @drjkyl.bsky.social · 5d

A Preliminary Prospective Study on the Association of Polymorphisms in BDNF, ARRB2 and KCNJ6 and Response to Fentanyl for Pain Management in Advanced Cancer
@cancer-control.bsky.social
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#cancercare #dosingguidelines #pharmacogenomics

Jen L, PhD @drjkyl.bsky.social · 5d

Effect of dapagliflozin on proteinuria and the slope of the estimated glomerular filtration rate in patients with immunoglobulin A nephropathy: A multicenter prospective study
Journal of International Medical Research
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#kidneyresearch

Reposted by Jen L, PhD

Natural Product Communications @naturalproductcomm.bsky.social · 6d

🦠 Phytochemicals in the Transmission Control of Epidemic Viruses: A Review Focused on SARS-CoV-2, Zika, and Dengue 🤚🏽
An analysis of the antiviral potential of phytochemicals and their applications in the prevention and treatment of SARS-CoV-2, Zika, and dengue.
journals.sagepub.com/doi/10.1177/...

Reposted by Jen L, PhD

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · 6d

📊 HIV from injection drug use is climbing (2016–2022).
PrEP uptake in PWID remains critically low.
Call to action: integrate ID + addiction care, expand low-barrier services, implement LA-PrEP, and fight stigma through policy + education.
journals.sagepub.com/doi/full/10....

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

journals.sagepub.com

Reposted by Jen L, PhD

Lingling Tian @linglingtian.bsky.social · 5d

🚨Call for Papers: @tamedoncol.bsky.social invites submissions on Antibody Drug Conjugates (ADCs) in Gynecologic Cancers. Led by Dr. Angélica Nogueira Rodrigues & Dr. Rowan Miller, this collection spotlights innovative ADC research in gynecologic oncology. 📥 Submit your work. buff.ly/RhdEIHX

Reposted by Jen L, PhD

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 5d

Systematic review & network meta-analysis in advanced EGFR-mutated #NSCLC after TKI failure: chemo+ivonescimab ranked best for PFS with acceptable safety; chemo+amivantamab gave strongest OS/ORR but higher toxicity. Chemo+IO or chemo alone less effective.

journals.sagepub.com/doi/epdf/10....

Reposted by Jen L, PhD

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 5d

Propensity-matched study (n=127) in extensive-stage #SCLC after first-line chemoimmunotherapy: prophylactic cranial irradiation (PCI) did not improve OS overall but reduced brain metastases (1-yr 13.8% vs 53.4%). OS benefit seen in partial responders.

journals.sagepub.com/doi/epdf/10....

Reposted by Jen L, PhD

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 5d

Study of 2896 early-stage #BreastCancer pts: CanAssist Breast prognostic test stratified ER1–20% subgroup. 65% classified low risk with 91% DRFI, 35% high risk with 61% DRFI. CAB may guide tailored therapy beyond ER levels in this challenging group.

journals.sagepub.com/doi/epdf/10....

Reposted by Jen L, PhD

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 5d

Phase III FLINTER trial (N=317) shows rituximab biosimilar DRL_RI is equivalent to MabThera® in untreated low–tumor-burden follicular lymphoma: BORR 80.2% vs 79.4% (Δ0.9%, CI within ±17%). Safety, immunogenicity, PK/PD profiles comparable. #Lymphoma

journals.sagepub.com/doi/epdf/10....

Reposted by Jen L, PhD

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 5d

Review outlines strategies for 10–20 mm non-pedunculated colorectal polyps: CSP offers low AE risk, modified EMR boosts en bloc rates by 15–20%, while ESD is preferred for invasive/fibrotic cases. Emerging bipolar/low-power snares may cut thermal AEs.

journals.sagepub.com/doi/epdf/10....

Reposted by Jen L, PhD

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 5d

The EARLY study will track patients with incidental, asymptomatic IBD to uncover genetic, immune & clinical markers of disease in its preclinical phase. With 10-year follow-up, it aims to predict outcomes & guide early intervention strategies.

journals.sagepub.com/doi/epdf/10....